Safety and efficacy of once-daily nevirapine dosing: a multicohort study

被引：9

作者：

Calmy, Alexandra ^{[1
]}

Vallier, Nathalie ^{[1
]}

Nguyen, Alain ^{[1
]}

Lange, Joep M. A. ^{[2
]}

Battegay, Manuel ^{[3
]}

de Wolf, Frank ^{[4
]}

Reiss, Peter ^{[2
]}

Lima, Viviane D. ^{[5
]}

Hirschel, Bernard ^{[1
]}

Hogg, Robert S. ^{[5
,6
]}

Yip, Benita ^{[5
]}

Montaner, Julio S. G. ^{[5
,7
]}

Wit, Ferdinand W. ^{[2
]}

机构：

[1] Univ Hosp Geneva, Div Infect Dis, HIV Unit, Geneva, Switzerland

[2] Univ Amsterdam, Acad Med Ctr, Dept Infect Dis Trop Med & AIDS, Ctr Poverty Related Communicable Dis,AIGHD, NL-1105 AZ Amsterdam, Netherlands

[3] Univ Basel Hosp, Div Infect Dis, CH-4031 Basel, Switzerland

[4] HIV Monitoring Fdn, Amsterdam, Netherlands

[5] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Populat Hlth Program, Vancouver, BC V6Z 1Y6, Canada

[6] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada

[7] Univ British Columbia, Fac Med, Vancouver, BC, Canada

来源：

ANTIVIRAL THERAPY | 2009年 / 14卷 / 07期

基金：

加拿大健康研究院;

关键词：

EARLY VIROLOGICAL FAILURE; HIV-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; DAILY DIDANOSINE; NAIVE; REGIMENS; RISK; STAVUDINE; EFAVIRENZ; RASH;

D O I：

10.3851/IMP1418

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background: Nevirapine (NVP) is often prescribed once daily in clinical practice in combination with a once daily nucleoside backbone. We investigated the relationship of NVP dosing with safety and efficacy. Methods: Patients from the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort study, Canadian HAART Observational Medical Evaluation and Research (HOMER) cohort and Swiss HIV Cohort Study (SHCS) using NVP-based combination therapy either once daily or twice daily were included. Risk factors for discontinuing NVP because of hypersensitivity reactions (HSRs) were investigated using multivariate logistic regression. Risk factors for virological failure 96 weeks after NVP initiation were identified using logistic regression and Cox models. Results: Of 5,636 patients (774 once daily and 4,862 twice daily), 268 (4.8%) discontinued NVP because of HSR between 2 and 18 weeks. Logistic regression showed that, compared with patients with detectable HIV type-1 (HIV-1) RNA starting twice-daily NVP, there was a significantly higher risk of discontinuation of once-daily NVP because of HSR in patients with detectable HIV-1 RNA at the start of NVP (odds ratio [OR] 1.52; P=0.04), whereas the risk was actually significantly lower in patients starting once-daily NVP with undetectable HIV-1 RNA (OR 0.44; P=0.04). Cox models showed that risk of virological failure was not different for twice- versus once-daily NVP in treatment-naive patients (twice-daily versus once-daily hazard ratio [HR] 1.01; P=0.95), treatment-experienced patients experiencing treatment failure (twice-daily versus once-daily HR 1.22; P=0.30) or patients with undetectable HIV-1 RNA simplifying treatment with NVP (twice-daily versus once-daily HR 1.29; P=0.30). Conclusions: Initiation of a once-daily NVP-based regimen in patients with suppressed viraemia carries a low risk of treatment-limiting HSR. Once- or twice-daily NVP-based regimens appear to have similar antiretroviral efficacy.

引用

页码：931 / 938

页数：8

共 24 条

[1] Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs [J].

Ananworanich, J ;

Moor, Z ;

Siangphoe, U ;

Chan, J ;

Cardiello, P ;

Duncombe, C ;

Phanuphak, P ;

Ruxrungtham, K ;

Lange, J ;

Cooper, DA .

AIDS, 2005, 19 (02) :185-192

[2]

[Anonymous], 7 INT C DRUG THER HI

[3] Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy [J].

Antinori, A ;

Baldini, F ;

Girardi, E ;

Cingolani, A ;

Zaccarelli, M ;

Di Giambenedetto, S ;

Barracchini, A ;

De Longis, P ;

Murri, R ;

Tozzi, V ;

Ammassari, A ;

Rizzo, MG ;

Ippolito, G ;

De Luca, A .

AIDS, 2001, 15 (12) :1579-1581

[4] Sex differences in nevirapine rash [J].

Bersoff-Matcha, SJ ;

Miller, WC ;

Aberg, JA ;

van der Horst, C ;

Hamrick, HJ ;

Powderly, WG ;

Mundy, LM .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (01) :124-129

[5] Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review [J].

Cooper, C. L. ;

van Heeswijk, R. P. G. .

HIV MEDICINE, 2007, 8 (01) :1-7

[6] GLOBAL HEALTH Rationing Antiretroviral Therapy in Africa - Treating Too Few, Too Late [J].

Ford, Nathan ;

Mills, Edward ;

Calmy, Alexandra .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (18) :1808-1810

[7] Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection:: the Scan Study [J].

García, F ;

Knobel, H ;

Sambeat, MA ;

Arrizabalaga, J ;

Aranda, M ;

Romeu, J ;

Dalmau, D ;

Segura, F ;

Gomez-Sirvent, JL ;

Ferrer, E ;

Cruceta, A ;

Gallart, T ;

Pumarola, T ;

Miró, JM ;

Gatell, JM .

AIDS, 2000, 14 (16) :2485-2494

[8] Pharmacokinetics of nevirapine: Once-daily versus twice-daily dosing in the 2NN study [J].

Kappelhoff, BS ;

Huitema, ADR ;

van Leth, F ;

Robinson, PA ;

MacGregor, TR ;

Lange, JMA ;

Beijnen, JH .

HIV CLINICAL TRIALS, 2005, 6 (05) :254-261

[9] Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-Infected patients [J].

Lapadula, Giuseppe ;

Costarelli, Silvia ;

Quiros-Roldan, Eugenia ;

Calabresi, Alessandra ;

Izzo, Ilaria ;

Carosi, Giampiero ;

Torti, Carlo .

CLINICAL INFECTIOUS DISEASES, 2008, 46 (07) :1127-1129

[10]

Mocroft A, 2007, ANTIVIR THER, V12, P325

← 1 2 3 →